40 results
8-K
EX-99.1
0esxhrw4 jsnm
3 Nov 22
Annexon Reports Third Quarter 2022 Financial Results and Plans to Provide Updates on Complement Therapeutic Portfolio in January 2023
6:45am
8-K
EX-99.1
nr287qckywv0a76xj9
8 Aug 22
Annexon Biosciences Highlights Business and Portfolio Progress and Key Anticipated Milestones and Reports Second Quarter 2022 Financial Results
4:30pm
8-K
EX-99.1
ufycp5r1z ecsq
9 May 22
Annexon Biosciences Highlights Portfolio Progress and Key Anticipated Milestones, and Reports First Quarter 2022 Financial Results
4:20pm
8-K
EX-99.1
dmdukf6yxgbq7009uo0j
7 Apr 22
Annexon Biosciences Completes Enrollment in ARCHER Phase 2 Trial of Novel C1q Inhibitor, ANX007, in Patients with Geographic Atrophy
5:27pm
8-K
EX-99.1
ijikxrr05zxh2o7juk7
20 Jan 22
Annexon Biosciences Appoints Bettina M. Cockroft, M.D. to its Board of Directors
4:05pm
8-K
EX-99.1
v8tf8ituxrx jla
4 Jan 22
ANX005 Has Been Generally Well-Tolerated and Has Shown Full Target Engagement of C1q in the CSF
4:16pm
8-K
EX-99.1
x5qkj
9 Nov 21
Annexon Biosciences Announces Business and Program Highlights and Reports Third Quarter 2021 Financial Results
4:16pm